Other Events ·
Ensysce Biosciences received Nasdaq notification confirming compliance with the $2.5 million stockholders' equity…
ENSCWEnsysce Biosciences, Inc.
Ensysce Biosciences received Nasdaq notification confirming compliance with the $2.5 million stockholders' equity requirement, though it must demonstrate continued compliance in its next periodic report to avoid delisting. Additionally, Nasdaq granted an extension until February 22, 2027, to regain compliance with the $1.00 minimum bid price requirement following a prior notice of non-compliance. The filing also discloses that the August 5, 2026 acquisition of Cy Biopharma constitutes a Change of Control under Nasdaq rules, requiring the post-transaction entity to satisfy initial listing criteria and complete an initial listing process before converting preferred stock issued in the transaction. Failure to meet these requirements could result in trading suspension. Ensysce Biosciences operates in the biotechnology industry, focusing on developing therapies for rare diseases.